DSMB recommends continuing BriaCell Phase 3 breast cancer study
BriaCell Therapeutics said its independent Data Safety Monitoring Board (DSMB) recommended continuing its Phase 3 metastatic breast cancer study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.